By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
ICCNICCNICCN
  • Home
  • Conferences
  • Events
  • Media
  • Publications
  • Resources
    • NCCN
    • ASCO
    • Hematology
Reading: ASH 2025 Annual Meeting
Sign In
Font ResizerAa
Font ResizerAa
ICCNICCN
  • Home
  • Conferences
  • Events
  • Media
  • Publications
  • Resources
Search
  • Home
  • Conferences
  • Events
  • Media
  • Publications
  • Resources
    • NCCN
    • ASCO
    • Hematology

Trending →

T-DXd Plus Pertuzumab Receives FDA Approval, Shifting the Frontline HER2-Positive Paradigm

By MedOnc2
December 15, 2025

FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA2-Mutated mCSPC

By MedOnc2
December 15, 2025

FDA Approves Durvalumab for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

By MedOnc2
December 15, 2025

FDA Grants Traditional Approval to Pirtobrutinib (Jaypirca®) for CLL/SLL

By MedOnc2
December 15, 2025

Enfortumab Vedotin + Pembrolizumab for Muscle-Invasive Bladder Cancer (MIBC)

By MedOnc2
November 22, 2025
Login Sign In
Follow US
© ICCN All Rights Reserved.
Conferences

ASH 2025 Annual Meeting

MedOnc2
Last updated: August 10, 2025 12:27 pm
By MedOnc2
Share
1 Min Read
SHARE

The 67th American Society of Hematology  (ASH) Annual Meeting and Exposition will be held in Orlando, Florida, and virtually, from December 6-9, 2025. The meeting will take place at the Orange County Convention Center

Dates:

December 6-9, 2025. 

Location:

Orlando, Florida, and online (virtual platform). 

Virtual Platform: 

The virtual platform will open on December 3, 2025, and will offer live and on-demand sessions, networking, and exhibits. 

Registration: 

ASH member registration is open, while registration for non-members, groups, exhibitors, and media will open on August 13, 2025, at 11:00 a.m. Eastern time. 

Exhibits: 

The in-person exhibit hall will be open December 6-8, 2025. 

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Tumblr Reddit Email Copy Link Print

Recent Posts

  • T-DXd Plus Pertuzumab Receives FDA Approval, Shifting the Frontline HER2-Positive Paradigm
  • FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA2-Mutated mCSPC
  • FDA Approves Durvalumab for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
  • FDA Grants Traditional Approval to Pirtobrutinib (Jaypirca®) for CLL/SLL
  • Enfortumab Vedotin + Pembrolizumab for Muscle-Invasive Bladder Cancer (MIBC)

Recent Comments

No comments to show.

You Might Also Like ↷

SOHO 2025 Meeting

August 13, 2025

ESMO Congress 2025

August 11, 2025
Interactive Cancer Care Network

Powered By Designjoom-Empowering Brands since 2010